BridgeBio Shares Data On Serum TTR Increase When Switching Participants From Placebo And Tafamidis To Acoramidis In ATTRibute-CM And Its Open-Label Extension; Showed A 42% Reduction In Composite CVH And ACM, And A 50% Reduction In The Cumulative...
BridgeBio Shares Data On Serum TTR Increase When Switching Participants From Placebo And Tafamidis To Acoramidis In ATTRibute-CM And Its Open-Label Extension; Showed A 42% Reduction In Composite CVH And ACM, And A 50% Reduction In The Cumulative...
BridgeBio在ATTRibute-Cm及其開放標籤延伸研究中分享了將參與者從安慰劑和他法米地切換到阿科莫地斯後的血清TTR增加數據；顯示出綜合心血管事件和ACm的減少42%，累積死亡和心血管急性事件的減少50%。
BridgeBio Shares Data On Serum TTR Increase When Switching Participants From Placebo And Tafamidis To Acoramidis In ATTRibute-CM And Its Open-Label Extension; Showed A 42% Reduction In Composite CVH And ACM, And A 50% Reduction In The Cumulative Frequency Of CVH Events Relative To Placebo At Month 30
BridgeBio在ATTRibute-Cm及其開放標籤延伸研究中分享了從安慰劑和Tafamidis切換參與者到Acoramidis時血清TTR的增加數據；在第30個月，相對於安慰劑，綜合CVH和ACm減少了42％，CVH事件的累積頻率降低了50％。
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the OLE (n=21) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18)
- 在從ATTRibute-Cm研究中將Tafamidis和安慰劑切換到其開放標籤延伸研究中的參與者（OLE），OLE一個月時血清轉甲狀腺素（TTR）平均增加3.0mg/dL（n=21），OLE六個月時血清TTR平均增加3.4mg/dL（n=18）。
- Increased...
-...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間